Medicare GLP-1: Bridge or Part D — which path is yours?
If you feel stuck between the $50 Medicare GLP-1 Bridge and your regular Part D plan, here’s the thing that settles it: the deciding factor is the indication the GLP-1 is prescribed for — not the drug’s name. Here’s how CMS draws the line, and the exact criteria it published.
The one rule that decides it: indication, not drug
Medicare routes GLP-1 medications by what they’re prescribed for. Per CMS’s provider guidance, a GLP-1 prescribed for a Part D–covered indication goes through Part D; a GLP-1 for weight management (if you meet the clinical criteria) can go through the GLP-1 Bridge. In CMS’s words: [v2-9]
“Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) indications are eligible for Part D coverage. Beneficiaries with these diagnoses … are ineligible to receive them through the Medicare GLP-1 Bridge, even if they otherwise meet the Medicare GLP-1 Bridge clinical criteria.” — CMS, Information for Providers
The published clinical criteria (three tiers)
CMS has published the Bridge’s clinical criteria. To qualify, a beneficiary must be at least 18, prescribed the drug to reduce excess body weight and maintain weight reduction alongside ongoing lifestyle modification, and meet any one of the following at the time GLP-1 therapy was initiated — the prescribing provider attests to this in the prior-authorization request (CMS): [v2-7]
| Tier | BMI (at initiation) | Plus a diagnosis of… |
|---|---|---|
| 1 | ≥ 35 | — (BMI alone) |
| 2 | ≥ 30 | heart failure with preserved ejection fraction; or uncontrolled hypertension (SBP > 140 or DBP > 90 despite two antihypertensive medications); or CKD stage 3a or above |
| 3 | ≥ 27 | pre-diabetes (ADA-defined); or previous heart attack; or previous stroke; or symptomatic peripheral artery disease |
Note: pre-diabetes is a qualifying comorbidity here — a type 2 diabetes diagnosis, by contrast, routes you to Part D (above). [v2-7][v2-9]
Per CMS, you must meet the criteria at the time GLP-1 therapy was initiated — not at the prior-auth request — including if you started before Part D enrollment or before the July 1, 2026 launch. CMS’s own example: someone who started in September 2024 at BMI 37 and is at BMI 34 by a July 2026 request — the provider attests the BMI ≥35 criterion was met at initiation. For long-term users whose weight has come down, this is the key detail. [v2-8]
Drugs, formulations, and cost
- Covered drugs: Foundayo (all formulations), Wegovy (all formulations), and Zepbound — only the KwikPen formulation. The single-dose vial and single-dose pen of Zepbound are not available through the Bridge, so a vial prescription won’t go through (CMS). [v2-5][v2-6]
- Cost: a $50 copay. Because the Bridge sits outside the Part D benefit, the Part D deductible doesn’t apply, none of the $50 counts toward your TrOOP total, and no low-income subsidy (LIS) applies (CMS). [v2-3]
- How it’s run: the Bridge operates outside the Part D benefit; in 2026 CMS uses a single central processor to handle prior authorization, claims, and pharmacy payment — providers submit the PA to that processor, not to individual Part D plans (CMS). [v2-4]
A quick self-check
- Are you enrolled in a Medicare Part D plan (standalone PDP or MA-PD)? You need this to use the Bridge (CMS). [v2-10]
- Is the GLP-1 prescribed for a Part D–covered indication (type 2 diabetes, OSA, MASH)? If yes → Part D, and the Bridge is off the table for that drug. [v2-9]
- Is it for weight management, and did you meet a BMI tier at initiation? If yes → likely the Bridge; your provider attests in the PA. [v2-7][v2-8]
If a determination goes against you
Whether it’s a Bridge prior-authorization decision or a Part D coverage determination, an adverse decision carries appeal rights. We won’t promise an outcome, but the rights exist and an unfiled appeal recovers nothing. Our step-by-step appeal guide covers the process, and IntelClaim can help you build the appeal for free.
This page summarizes public CMS guidance for the Medicare GLP-1 Bridge (CMS pages last modified June–July 2026) and is general information, not medical or insurance advice. CMS notes the covered product and NDC lists may be updated. Always confirm current rules on the official CMS Medicare GLP-1 Bridge page and check what applies to your own plan and prescription.
Frequently asked questions
How do I know whether I go through the Bridge or Part D?
It comes down to what the GLP-1 is prescribed for, not the drug itself. Per CMS, if it is prescribed for a Part D–covered indication (type 2 diabetes, moderate-to-severe OSA, or noncirrhotic MASH), it goes through your Part D plan. If it is for weight management and you meet the clinical criteria, it can go through the Bridge at the $50 copay. [v2-9]
I started my GLP-1 years ago and my BMI has dropped — do I still qualify?
Possibly. Per CMS, you must meet the clinical criteria at the time GLP-1 therapy was initiated, not at the time of the prior-authorization request — including if you started before enrolling in Part D or before the July 1, 2026 launch. CMS gives the example of someone who started in September 2024 at BMI 37 and is at BMI 34 by a July 2026 request: the provider attests the BMI ≥35 criterion was met at initiation. [v2-8]
What exactly are the BMI criteria?
There are three tiers (meet any one, at the time therapy was initiated): BMI ≥35; or BMI ≥30 with heart failure with preserved ejection fraction, uncontrolled hypertension, or CKD stage 3a+; or BMI ≥27 with pre-diabetes (ADA-defined), prior heart attack, prior stroke, or symptomatic peripheral artery disease. The prescribing provider attests to this in the prior-authorization request. [v2-7]
What will I pay, and are there hidden costs?
A $50 copay. Because the Bridge runs outside the Part D benefit, CMS states the Part D deductible does not apply, none of the $50 counts toward your TrOOP total, and no low-income subsidy (LIS) applies. [v2-3]
Coverage or prior auth denied? Appeal it free
IntelClaim helps you build a clear, evidence-backed appeal or prior-authorization request — free, purpose-built, and self-help.
IntelClaim is a self-help tool — not legal, medical, or insurance advice — and does not guarantee any particular outcome. Information on this site is general and may not reflect the rules of your specific plan or state. Always read your own denial letter, plan documents, and the deadlines that apply to you, and consider professional advice for your situation. No PHI is collected on this marketing site.